Bulger E M, Maier R V
Department of Surgery, University of Washington, Harborview Medical Center, Seattle 98104, USA.
Crit Care Med. 2000 Apr;28(4 Suppl):N27-36. doi: 10.1097/00003246-200004001-00004.
Inflammatory lipid mediators are produced by the metabolism of membrane phospholipids following a number of different stimuli. These mediators lead to a variety of cellular and systemic responses which contribute to the manifestations of the systemic inflammatory response syndrome in the critically ill patient. These mediators include platelet-activating factor and the eicosanoids, including prostaglandins, thromboxanes, leukotrienes, and HETEs. This review seeks to evaluate the current role of these mediators in the pathophysiology of critical illness. We will focus on recent studies concerning the modulation of these pathways as a potential therapeutic strategy for management of these critically ill patients. This includes the gamut from nutritional strategies to alter the cellular membrane lipid composition, thereby effecting the substrate available to produce these lipid byproducts, to intracellular inhibitors to alter production of these mediators, to receptor blockage and enhanced clearance to inhibit their effects.
炎症性脂质介质是在多种不同刺激下由膜磷脂代谢产生的。这些介质会引发多种细胞和全身反应,这些反应导致了重症患者全身炎症反应综合征的表现。这些介质包括血小板活化因子和类花生酸,其中类花生酸包括前列腺素、血栓素、白三烯和羟二十碳四烯酸。本综述旨在评估这些介质在危重病病理生理学中的当前作用。我们将重点关注近期有关调节这些途径作为管理这些重症患者潜在治疗策略的研究。这包括从营养策略(改变细胞膜脂质组成,从而影响产生这些脂质副产物的可用底物)到细胞内抑制剂(改变这些介质的产生),再到受体阻断和增强清除以抑制其作用的一系列方法。